🇺🇸 FDA
Pipeline program

Roflumilast foam 0.3%

ARQ-154-204

Phase 2 small_molecule completed

Quick answer

Roflumilast foam 0.3% for Plaque Psoriasis is a Phase 2 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcutis Biotherapeutics
Indication
Plaque Psoriasis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials